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fraction for all patients, using a balloon applicator (ranging 
from 3-4 and 4-5cm in diameter) placed into the surgical bed. 
Distance from the applicator to the skin surface was verified 
intraoperatively through ultrasound monitoring. Energy of 50 
kV was used, in a dose of 20 Gy prescribed to the surface of 
the balloon, with a mean treatment duration of 550 seconds. 
Protection of the chest wall was performed with an 
attenuation disk that varied between 4 and 6 cm in diameter. 
Clinical, surgical and pathologic parameters, as well as the 
immediate and late toxicity were evaluated using the EORTC 
score. 
Results: The median age of the patients was 65 years (range 
42 to 89), stage pTisN0M0, pT1N0M0 and pT2N0M0. All patients 
had sentinel node assessment in the OR. Tumor size ranged 
between 0.4 and 2 cm. In 57% of the cases, the pathology 
revealed invasive ductal carcinoma without an extensive 
intra-ductal component. There were no post-operative 
complications and the immediate skin reaction was mild, 
without any grade 3/4 acute toxicity or delayed healing. Two 
cases of seroma and two cases of mild subcutaneous fibrosis 
were reported. With a median follow-up of 18 months, there 
were no local recurrences. There was one case of axillar 
recurrence one year after treatment. 
Conclusions: IORT using the Electronic Brachytherapy 
System® by Xoft as part of the conservative treatment of 
breast cancer is a safe procedure, with low morbidity. The 
low incidence of side effects as well as the short treatment 
time inside the OR has led to a growing interest in using this 
treatment solution. Following these patients will allow us 
monitoring any delayed reactions and subsequent cosmetic 
effect as well as the local control rate and survival.  
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Purpose/Objective: Intraoperative Electron Radiation 
Therapy (IOERT) has been demonstrated to be a good method 
of treatment of early breast cancer (BC) in selected patients 
(pts). In this study we evaluate the efficacy of a single dose 
of 18Gy given to the tumor bed during the surgery in order to 
reduce late toxicity with respect to the standard 21 Gy dose. 
Materials and Methods: From January 2009 to December 
2011, 72pts with diagnosis of early BC underwent IOERT as 
exclusive treatment after breast conservative surgery. The 
median age was 66 years (range 47–84). The criteria of 
eligibility were: tumors smaller than 10mm, sentinel node 
N0, negative surgical margins (≥5mm). All pts received 
standard dose of 18Gy with electrons beams of 4-10 Mev 
energy, given by a mobile linear dedicated accelerator. The 
choice of the collimator diameter was based on the primary 
tumor size and site (range 40mm-60mm): the most used was 
50mm, in 48\73 pts (66%). The protection of the thoracic wall 
was achieved using aluminum discs of diameter 7cm (range 5-
8). 
Results: With median follow up of 36 months (range 12-60) in 
all patients the acute and subacute toxicity was mild, there 
were no delays healing, wound dehiscence or infection. Late 
toxicity (fibrosis) at one year was G0 in 32pts(43%), G1 in 
26pts(36%),G2 in 15(20%). At 2years: G0 in 46pts(64%),G1 in 
22 pts(30%),G2 in 4pts(6%). At 3 years G0 in 52pts(73%),G1 in 
20pts(17%). At 4 years we have 23 pts in follow-up and only 
8pts(35%) have fibrosis G1. The aesthetic result is 
excellent/good in 87% pts , acceptable in 13%. One patient 
submitted local recurrence (1.4%) 
Conclusions: The short follow up and the limited number of 
patients do not allow us not to draw definitive conclusions, 
but at present patients are not experiencing an excess of 
local relapse with the 18Gy single IOERT dose. 
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Purpose/Objective: To investigate the ability for rescanned 
PBS proton therapy to recover the dose distributions in 
mobile lung tumours, with phantom measurements within a 
dynamic,anthropomorphic,thorax phantom. 
Materials and Methods: For dosimetric measurements in a 
geometry similar to a lung cancer patient,a 
dynamic,anthropomorphic thorax phantom was employed. 
This consists of a tumour (wooden sphere) moving within an 
inflating lung,enclosed in a rib cage,complete with 
intercostal muscle and skin layers. Three planes of 
Gafchromic film in the coronal plane were used to measure 
the dose distributions resulting from PBS proton therapy for a 
range of rescan factors (≤8) and peak-to-peak motion 
amplitudes (4-10 mm). A PBS treatment was planned using an 
in-house planning system. The ITV was generated from the 
maximum excursion of the target as visualised on the mean 
projection CT calculated from a 4DCT scan. Two Single Field 
Uniform Dose (SFUD) fields (1.8 Gy prescribed dose) were 
employed at the following angles (gantry, couch): (-25,30), 
(45,0). To allow for up to 8-times scaled,volumetric re-
scanning per field, optimization of each field was performed 
with an 8-times higher cut-off for the lowest deliverable 
pencil beam weight. Prior to delivery,phantom and film 
positioning was checked and corrected using CT imaging,as 
performed for all patients. Table shifts were applied to 
match the ribs,and the tumour mid-ventilation position was 
aligned cranio-caudally by adjusting the position of the 
tumour in the lung. The phantom was programmed to move 
with a sinusoidal motion with maximum excursions of up to 4 
and 10 mm for deliveries with rescan factors between 1 and 
8. Reference films were acquired with the phantom and 
tumour stationary, and with a moving tumour with no 
rescanning. 
Results: Hot spots of up to 116% of the prescribed dose,with 
a pattern typically expected with the interplay effect,were 
clearly observed on the film with 10 mm motions (see Figure 
1),while with 4 mm motion, only a faint interplay pattern 
was observed. However,experimental error translating to an 
uncertainty in the homogeneity index (D5-D95) of typically 5% 
shadowed this result. With a rescan factor of 8, even in the 
case of 10 mm motion,dose homogeneities similar to those of 
the static case could be achieved (D5-D95 of static and 10 mm 
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motion was 8.4% and 8.8% respectively). Full results can be 
found in Table 1. 
Table 1: Data for the cases measured at 4mm and 10mm 
motion with variable rescanning,evaluated with D5-D95. 
RS=Rescan factor 
 
 
Figure 1: (Top) Central plane of target at 10 mm motion,with 
variable rescan factors (+static),normalised to mean dose of 
rescan factor=8 case (100% = 1.73 Gy). (Bottom) DVH 
corresponding to the above cases extracted three film 
measurement. 
 
Conclusions: Scaled,volumetric rescanning of PBS proton 
therapy has been shown to deliver clinically acceptable dose 
distributions in an anatomically realistic lung motion 
phantom,provided a large enough rescan factor is used. For 
single field delivery,8 times rescanning was found to be 
necessary for motions of 10 mm,with little or no re-scanning 
required for motion of 4 mm.  
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Purpose/Objective: This report of ASCENDE-RT* compares 
the efficacy of low-dose-rate prostate brachytherapy (LDR-
PB) to dose-escalated external beam radiation therapy (DE-
EBRT) for men with National Comprehensive Cancer Network 
(NCCN) intermediate- and high-risk prostate cancer.  
Materials and Methods: A total of 398 patients were accrued 
to a randomized trial at 6 institutions, stratified by risk group 
(276 high, 122 intermediate) and randomized (1:1) to one of 
two treatment arms. All patients had androgen deprivation 
therapy (ADT) for a total of 12 months using depot LHRH 
agonist injections and at least 4 weeks of oral anti-androgen 
coverage. After 8 month of neo-adjuvant ADT, all patients 
received four-field pelvic EBRT (46 Gy/23#). Those assigned 
to the DE-EBRT arm (N=200) continued with an additional 32 
Gy in 16# via a 2-phase, 3-d conformal technique without 
interruption in treatment. The men assigned to the LDR-PB 
arm (N=198) received an 125Iodine LDR-PB implant after a two 
week break (MPD = 115 Gy). Disease free survival (DFS) using 
the nadir+2 ng/mL (Phoenix) definition of biochemical failure 
was the primary endpoint. For actuarial analysis, time was 
calculated from the date of the first LHRH injection. No 
patients were excluded and all reported results are based on 
an intent-to-treat analysis. 
Results: Twelve major protocol violations occurred in each 
arm. The median follow up (FU) is 6.5 years. Compared to 
the DE-EBRT arm, men assigned to LDR-PB boost were more 
than twice as likely to remain disease free using the standard 
Phoenix definition for biochemical relapse (hazard ratio = 
0.473; 95% CI 0.292 - 0.765; P = 0.0022), with the 7-yr K-M 
DFS of 86% (LDR-PB) vs 75% (DE-EBRT). Employing a alternate 
(surgical-type) threshold of >0.2 ng/mL to define PSA 
relapse, resulted in a 7-yr K-M DFS estimate of 82% for men 
randomised to LDR-PB compared to only 39% for men assigned 
to DE-EBRT boost (p<0.0001). There have been 68 deaths in 
total resulting in a K-M overall survival (OS) estimate of 83% 
at 7-yrs; the most common cause of death was prostate 
cancer (N=18) followed by heart disease (N=14), and lung 
cancer (N=7). There have been 38 deaths among those men 
assigned to DE-EBRT, 13 of whom had recurrent prostate 
cancer including 11 with documented metastatic disease. By 
comparison, there have been 30 deaths among men assigned 
to LDR-PB; 7 of whom had recurrent prostate cancer and 
documented metastases. 
 
 
Conclusions: In multi-centre randomized setting, an LDR-PB 
boost demonstrated a large advantage over a DE-EBRT boost 
in relation to the primary endpoint (DFS). To date, OS and 
prostate cancer-specific survival do not appear to differ 
between arms. However, existing trends favour LDR-PB, 
suggesting differences in these survival endpoints may well 
emerge with longer FU.  
*ASCENDE-RT: Androgen Suppression Combined with Elective 
Nodal and Dose Escalated Radiation Therapy is an NCI 
registered trial (NCT00175396).  
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